Late Endocrine and Metabolic Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi.
classical Hodgkin lymphoma
diffuse large B-cell lymphoma
gonadal dysfunction
lymphoma survivors
metabolic syndrome
osteoporosis
sarcopenia
thyroid disease
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Mar 2022
10 Mar 2022
Historique:
received:
27
09
2021
revised:
24
02
2022
accepted:
07
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
Overall survival after lymphoma has improved in recent years, but the high prevalence of late treatment-related sequelae has been observed as a counterpart. In this systematic review, FIL researchers aimed to: (i) estimate the incidence or prevalence of late endocrine-metabolic sequelae, (ii) evaluate the effects of modern therapeutic approaches on incidence or prevalence of late endocrine-metabolic sequelae, and (iii) determine whether there is evidence of follow-up schemes for their screening/early diagnosis in the subset of long-term classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) survivors treated at adult age. The MEDLINE, Embase and the Cochrane Library databases were searched for relevant articles published up to October, 2020. The study selection process was conducted by three independent reviewers and was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A risk of bias assessment was performed using the Cochrane tool for randomized trials and the Newcastle-Ottawa Scale for observational studies. In the final analysis, eight studies were included, four of which focused on thyroid disease, two on gonadal dysfunction, one on bone disease and one on metabolic syndrome. Hypothyroidism was reported in up to 60% of adult cHL survivors and was frequently recorded even with modern radiotherapy approaches. Menopause occurred in 52-72% of women after chemotherapy. An 86% reduction in vertebral density was reported following R-CHOP-like chemotherapy. Sarcopenia and metabolic syndrome were reported in 37.9% and 60% of patients, respectively. No validated screening protocols were found for the early diagnosis of long-term treatment-related endocrine and metabolic sequelae, thus the authors finally suggest the execution of screening exams according to the risk category which were identified in the epidemiologic studies.
Sections du résumé
BACKGROUND
BACKGROUND
Overall survival after lymphoma has improved in recent years, but the high prevalence of late treatment-related sequelae has been observed as a counterpart.
METHOD
METHODS
In this systematic review, FIL researchers aimed to: (i) estimate the incidence or prevalence of late endocrine-metabolic sequelae, (ii) evaluate the effects of modern therapeutic approaches on incidence or prevalence of late endocrine-metabolic sequelae, and (iii) determine whether there is evidence of follow-up schemes for their screening/early diagnosis in the subset of long-term classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL) survivors treated at adult age. The MEDLINE, Embase and the Cochrane Library databases were searched for relevant articles published up to October, 2020. The study selection process was conducted by three independent reviewers and was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A risk of bias assessment was performed using the Cochrane tool for randomized trials and the Newcastle-Ottawa Scale for observational studies.
RESULTS
RESULTS
In the final analysis, eight studies were included, four of which focused on thyroid disease, two on gonadal dysfunction, one on bone disease and one on metabolic syndrome. Hypothyroidism was reported in up to 60% of adult cHL survivors and was frequently recorded even with modern radiotherapy approaches. Menopause occurred in 52-72% of women after chemotherapy. An 86% reduction in vertebral density was reported following R-CHOP-like chemotherapy. Sarcopenia and metabolic syndrome were reported in 37.9% and 60% of patients, respectively. No validated screening protocols were found for the early diagnosis of long-term treatment-related endocrine and metabolic sequelae, thus the authors finally suggest the execution of screening exams according to the risk category which were identified in the epidemiologic studies.
Identifiants
pubmed: 35326591
pii: cancers14061439
doi: 10.3390/cancers14061439
pmc: PMC8946842
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Am J Med. 2001 May;110(7):563-72
pubmed: 11343670
J Clin Oncol. 2018 Jul 20;36(21):2169-2180
pubmed: 29874135
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Ann Hematol. 1994 Mar;68(3):105-10
pubmed: 8167175
Eur J Endocrinol. 2015 Aug;173(2):139-48
pubmed: 25947143
Surg Endosc. 2011 Jul;25(7):2241-6
pubmed: 21298536
Acta Haematol. 2018;139(4):235-237
pubmed: 29929199
Crit Rev Oncol Hematol. 2020 Jul;151:102981
pubmed: 32485429
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
Cancers (Basel). 2021 Jun 09;13(12):
pubmed: 34207634
Ann Oncol. 2014 Feb;25(2):481-6
pubmed: 24401926
Cancers (Basel). 2021 Jul 07;13(14):
pubmed: 34298616
Ann Oncol. 2015 Aug;26(8):1771-6
pubmed: 25962442
J Clin Oncol. 2014 Oct 10;32(29):3257-63
pubmed: 25154821
Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):11-31
pubmed: 25863750
J Endocrinol. 2016 May;229(2):R67-81
pubmed: 26931135
J Cancer Surviv. 2017 Jun;11(3):302-308
pubmed: 28028762
Thyroid. 2015 Jul;25(7):716-59
pubmed: 25900731
Cancers (Basel). 2021 Jun 14;13(12):
pubmed: 34198635
Arch Toxicol Suppl. 1984;7:140-5
pubmed: 6083763
Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):530-540
pubmed: 29681481
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e1-e9
pubmed: 28916153
Tumori. 2021 Feb;107(1):91-94
pubmed: 32116159
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):854-62
pubmed: 23790512
Hematol Oncol. 1992 May-Aug;10(3-4):181-7
pubmed: 1398514
Nat Rev Endocrinol. 2018 Sep;14(9):513-537
pubmed: 30065268
Arch Intern Med. 2009 Aug 10;169(15):1381-8
pubmed: 19667301
Leuk Lymphoma. 2007 Aug;48(8):1514-21
pubmed: 17701582
J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32
pubmed: 10999813
BMJ. 2017 Sep 21;358:j4008
pubmed: 28935701
J Pers Med. 2021 Mar 17;11(3):
pubmed: 33802940
Haematologica. 1999 Oct;84(10):917-23
pubmed: 10509040
J Clin Oncol. 2013 Jan 10;31(2):231-9
pubmed: 23150709
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813253
J Clin Pathol. 1985 Nov;38(11):1247-51
pubmed: 3934229
Ann Oncol. 1992 Sep;3 Suppl 4:105-10
pubmed: 1280463
Oncologist. 1996;1(1 & 2):62-67
pubmed: 10387970
Br J Cancer. 2009 Feb 10;100(3):455-63
pubmed: 19156143
Semin Hematol. 2016 Jul;53(3):209-15
pubmed: 27496313
Endocr Pract. 2012 Nov-Dec;18(6):988-1028
pubmed: 23246686
Cancers (Basel). 2021 Jan 08;13(2):
pubmed: 33429908
Acta Haematol. 2003;109(1):11-7
pubmed: 12486317
JAMA. 2004 Jan 14;291(2):228-38
pubmed: 14722150
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):323-330
pubmed: 27913498
JPEN J Parenter Enteral Nutr. 2011 Sep;35(5 Suppl):21S-8S
pubmed: 21807929
Ann Oncol. 2006 Sep;17(9):1428-33
pubmed: 16831852
Arthritis Rheumatol. 2017 Aug;69(8):1521-1537
pubmed: 28585373
Ann Hematol. 2000 Mar;79(3):114-8
pubmed: 10803932
Endocr Pract. 2016 May;22(5):622-39
pubmed: 27167915
Radiother Oncol. 2016 Mar;118(3):430-6
pubmed: 26993414
Lancet Diabetes Endocrinol. 2015 Jul;3(7):545-55
pubmed: 25873569
Acta Oncol. 2015 Jan;54(1):49-59
pubmed: 25140862
Hum Reprod. 2003 Jan;18(1):117-21
pubmed: 12525451
Cancers (Basel). 2021 Jun 23;13(13):
pubmed: 34201563
BMJ. 2001 Jun 23;322(7301):1509
pubmed: 11439984
Biol Blood Marrow Transplant. 2007 Oct;13(10):1153-9
pubmed: 17889351
Ann Oncol. 2015 Sep;26 Suppl 5:v116-25
pubmed: 26314773
J Clin Endocrinol Metab. 2003 Jun;88(6):2404-11
pubmed: 12788835
Leuk Lymphoma. 2017 May;58(5):1105-1113
pubmed: 27736260
Lancet Oncol. 2012 Oct;13(10):1002-10
pubmed: 22921663
Br J Cancer. 1994 Aug;70(2):371-5
pubmed: 8054287
Medicina (Kaunas). 2019 Jul 16;55(7):
pubmed: 31315290
Leuk Lymphoma. 2018 May;59(5):1180-1187
pubmed: 28862484
Diabetes Care. 2004 May;27(5):1036-41
pubmed: 15111517
Am Fam Physician. 2018 Nov 15;98(10):Online
pubmed: 30365294
Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):636-41
pubmed: 24521679
Am J Hematol. 2019 May;94(5):604-616
pubmed: 30859597
Int J Cancer. 2009 Nov 15;125(10):2400-5
pubmed: 19610069